Research on Early Diagnosis and Treatment of Gastric Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 25 July 2024 | Viewed by 1057

Special Issue Editor


E-Mail Website
Guest Editor
Department of Gastroenterology, Akita University Graduate School of Medicine, 1-1, Tegata Gakuen-machi, Akita 010-8502, Japan
Interests: gastric cancer

Special Issue Information

Dear Colleagues,

Although gastric cancers (GCs) are decreasing worldwide, GC is still the sixth most common cancer and the third leading cause of cancer death; hence, further efforts are required to improve the prognosis of GC patients. In particular, GC is common in East Asia, where measures to reduce the number of GC-related deaths are of high importance. In practice, Japan and South Korea successfully introduced a health-check program for residents in order to detect GC at an early stage and treat it curatively. Early diagnosis and treatment are the most effective measures to reduce GC mortality and it is necessary to further advance this field in the future. This topic calls for the latest research reports on the early diagnosis and treatment of GC.

Prof. Dr. Katsunori Iijima
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 512 KiB  
Article
Helicobacter pylori Eradication Does Not Adversely Affect the Clinical Course of Gastric Cancer: A Multicenter Study on Screening Endoscopic Examination in Japan
by So Takahashi, Kenta Watanabe, Sho Fukuda, Tatsuki Yoshida, Takahiro Dohmen, Junichi Fujiwara, Mari Matsuyama, Shusei Fujimori, Masato Funaoka, Kodai Shirayama, Yohei Horikawa, Saki Fushimi, Shu Uchikoshi, Kengo Onochi, Ryo Okubo, Takao Hoshino, Toru Horii, Taira Kuramitsu, Kotaro Sakaki, Toru Ishii, Taiga Komatsu, Yuko Yoshida, Kenji Shirane, Tsuyoshi Ono, Yosuke Shimodaira, Tamotsu Matsuhashi and Katsunori Iijimaadd Show full author list remove Hide full author list
Cancers 2024, 16(4), 733; https://doi.org/10.3390/cancers16040733 - 09 Feb 2024
Viewed by 713
Abstract
Background: Since gastric cancers (GCs) detected after Helicobacter pylori (HP) eradication present with different morphological characteristics from conventional HP-positive GCs, delayed detection of early-stage GCs may be observed. This study aimed to investigate the clinical impact of HP eradication on [...] Read more.
Background: Since gastric cancers (GCs) detected after Helicobacter pylori (HP) eradication present with different morphological characteristics from conventional HP-positive GCs, delayed detection of early-stage GCs may be observed. This study aimed to investigate the clinical impact of HP eradication on diagnosing GC during screening endoscopy. Methods: Eleven health checkup institutions in Japan participated in the present study. All GC cases newly diagnosed by screening endoscopy between January 2016 and December 2020 were included. After propensity score matching, multivariable regression analysis was performed to estimate the effect of HP eradication on deep tumor invasion among HP-eradicated and HP-positive GC cases. Results: A total of 231 patients with GCs (134 HP-eradicated and 97 HP-positive cases) were enrolled. After propensity score matching, there were 81 cases in each group. The distribution of the depth of tumor invasion (pT1a, pT1b1, pT1b2, and pT2) between the HP-eradicated group and HP-positive group was similar (p = 0.82). In the propensity analysis, with HP-positive as the reference value, HP eradication was not significantly associated with T1b–T4-GCs and T1b2–T4-GCs, with odds ratios (95% confidence intervals) of 1.16 (0.48–2.81) and 1.16 (0.42–3.19), respectively. Conclusions: HP eradication does not adversely affect the clinical course of GCs, supporting the recommendation of HP eradication in screening programs to reduce the total number of GC cases without delaying diagnosis. Full article
(This article belongs to the Special Issue Research on Early Diagnosis and Treatment of Gastric Cancer)
Show Figures

Figure 1

Back to TopTop